Clinical trials in Gliwice – page 2

164 clinical trials in Gliwice, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Gliwice at a glance

164

clinical trials

Research sites1

Quick filters

164 trials in Gliwice

Open in trial search

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:BeOne Medicines I GmbH

Contact Research Centre

Hodgkin's disease

Recruiting

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Registered drugNo placebo

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Brentuximab Vedotin

Contact Research Centre

Non-Hodgkin's lymphoma

Recruiting

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Tocilizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Imeroprubart
Sponsor:Immunovant Sciences GmbH

Contact Research Centre

Renal cell carcinoma

Recruiting

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Plasma cell myeloma+1

Recruiting

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:AZD0120
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ASP-1929 and pembrolizumab for patients with recurrent head and neck squamous cell carcinoma without distant metastases

Registered drugNo placebo

Study of ASP-1929 and pembrolizumab for patients with recurrent head and neck squamous cell carcinoma without distant metastases

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Rakuten Medical Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gliwice

What the registry says about research in the country

01 Hematologic Oncology

Innovative trials focusing on chronic lymphocytic leukemia and various lymphomas, testing novel combination therapies and personalized treatment approaches.

B-cell lymphomas and leukemias
CAR T-cell therapy
Targeted therapies

Research includes assessment of venetoclax combinations and novel immunotherapy approaches for blood cancers.

02 Solid Tumors

Comprehensive studies examining treatments for advanced solid tumors, including breast, lung, and colorectal cancers.

Immunotherapy combinations
Targeted molecular therapies
Novel drug combinations

Investigations focus on improving survival outcomes through innovative treatment strategies.

03 Head and Neck Cancers

Clinical trials evaluating new approaches for head and neck squamous cell carcinoma and throat cancers using radiochemotherapy and immunotherapy.

Low-dose radiation therapy
Combination treatments
Novel immunotherapy agents

Studies aim to enhance treatment efficacy while minimizing side effects.

Back to Poland All countries